Key information

This information is provided for the purposes of AIM rule 26

Our Mission

Our Mission is to shape the future of medicine by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms.

Investment Opportunity

  • Avacta operates through two separate divisions in both the oncology drug development market and the diagnostics sector.
  • Avacta’s has two proprietary platform technologies – the Affimer® and pre|CISION™ platforms – which are being used to deliver a robust portfolio of differentiated therapeutic and diagnostic products that address multi-billion dollar markets.
  • Platform Technologies
    • Affimer® molecules are engineered alternatives to antibodies that have significant competitive advantages including size, stability, versatility, rapid development and ease of production. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100 billion.
    • The pre|CISION™ platform provides a mechanism for targeting the release of active chemotherapy to the tumour, thereby reducing systemic exposure and the side effects associated with many commonly used cancer treatments the effectiveness of which is limited by toxicity and tolerability for patients.
  • Therapeutic Opportunities
    • The Phase I trial for the first candidate, AVA6000, started in August 2021 and FDA approval of its Investigational New Drug (‘IND’) application was announced in November 2021. The Phase Ia dose escalation study is expected to complete in late 2022 and the Phase Ib dose expansion study to commence shortly afterwards.
    • There is also significant longer term potential to combine the two platforms to create next generation targeted ‘drug conjugate’ cancer treatments.
    • The platforms are also being developed through leading industry partnerships including LG Chem, Daewoong Pharmaceutical and POINT Biopharma.
    • The second pre|CISIONTM tumour targeted chemotherapy candidate for development was announced in January 2022 and is a proteasome inhibitor referred to as AVA3996. The Company plans to generate additional Affimer® and pre|CISION™ drug development to further support its growing, innovative therapeutic pipeline.
  • Diagnostics Opportunities
    • There are many factors driving growth in the diagnostic sector such as an aging population, the increasing incidence of chronic and infectious diseases, the influence of tech companies through digital health and devices and the increase in awareness of self-testing in a post-pandemic world.
    • The diagnostics sector is quite fragmented with a large number of small and medium sized companies which provides ideal conditions for an M&A led growth strategy to consolidate European diagnostics SMEs in a market with strong future growth drivers.
    • The Group has a platform and an experienced management team to execute an M&A led strategy to build a leading European IVD business.
    • Integrating the unique Affimer platform to develop new immunodiagnostic products and to help differentiate acquired products gives a clear advantage in a competitive market.
  • With its strong balance sheet, the Group expects to deliver major value inflection points from its therapeutic programmes over the next twelve months and grow revenues and cash generation from its expanded diagnostic business, driving long-term shareholder value.
  • The Group also anticipates further commercial partnerships and license arrangements that will allow its technology platforms to be further developed leading to long term royalty based revenue in both the therapeutics and other markets.


  • Drive shareholder value by building a portfolio of novel, clinically differentiated cancer therapies leveraging the key benefits of the Affimer®and pre|CISION™ platforms.
  • Build a fast-paced, nimble, delivery-focused drug discovery and development organisation with multiple clinical programmes and an innovative pre-clinical pipeline.
  • Establish partnerships with global pharmaceutical companies for our technology platforms and pipeline.
  • Deliver a focused and disciplined, but ambitious, M&A led growth strategy to build an integrated and differentiated in-vitro diagnostics (IVD) business with global reach serving professionals and consumers.

Significant Shareholdings

Current significant shareholders are as follows:

Premier Miton Group  – 4.66%

Baillie Gifford & Co Limited – 4.63%

Conifer Management, LLC – 2.99%

As at 27th January 2023 the company has 269,961,549 ordinary shares of 10p each in issue.

1.7% of the ordinary shares of the Company are not held in public hands.

Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.

There are no restrictions on the transfer of Avacta Group plc’s AIM securities.

Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.

Avacta Group plc is incorporated in the United Kingdom and its principal place of operation is the United Kingdom.

This information was last updated on 27th January 2023.


Dr Alastair Smith
Mr Tony Gardiner
Dr Eliot Forster
Dr Trevor Nicholls
Mr Paul Fry
Dr Mark Goldberg
Dr Christina Coughlin


Broker and Nomad – Stifel, 150 Cheapside, London, EC2V 6ET
Auditor – BDO LLP, Newton House, Cambridge Business Park, Cambridge, CB4 0WZ
Solicitor – Walker Morris, 33 Wellington Street, Leeds, LS1 4DL
Registrar – Link Group, 10th floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL.
Investor and Media Relations – FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.